NEWTOWN, Pa., Nov. 05, 2024 (GLOBE NEWSWIRE) -- The law firm of Edelson Lechtzin LLP is investigating claims regarding data privacy violations by Zydus Pharmaceuticals (USA) Inc. (“Zydus”). Zydus learned of suspicious activity on or about July 28, 2024. To join this case, go HERE.
About Zydus Pharmaceuticals (USA) Inc.
Zydus Pharmaceuticals (USA) Inc. operates as the U.S. generic drug branch of the global pharmaceutical leader, Zydus Lifesciences.
What happened?
On or about July 28, 2024, Zydus discovered unauthorized activity on its computer network. An investigation was launched, and it was determined that certain personal information may have been obtained in the data breach. This information may have included names in combination with other personal identifiers, including Social Security numbers, driver’s licenses, or other government identification numbers, and credit or debit card numbers. On October 29, 2024, Zydus began mailing data breach notification letters to impacted individuals.
How can I protect my personal data?
If you receive a data breach notification, you must guard against possible misuse of your personal information, including identity theft and fraud, by regularly reviewing your account statements and monitoring your credit reports for suspicious or unauthorized activity. Additionally, you should consider legal options for mitigating such risks.
Edelson Lechtzin LLP is investigating a class action lawsuit to seek legal remedies for customers who may have had their sensitive personal and patient data compromised by the Zydus data breach.
For more information, please contact:
Marc H. Edelson, Esq.
EDELSON LECHTZIN LLP
411 S. State Street, Suite N-300
Newtown, PA 18940
Phone: 844-696-7492
Email: medelson@edelson-law.com
Web: www.edelson-law.com
About Edelson Lechtzin LLP
Edelson Lechtzin LLP is a national class action law firm with offices in Pennsylvania and California. In addition to cases involving data breaches, our lawyers focus on class and collective litigation in cases alleging securities and investment fraud, violations of the federal antitrust laws, employee benefit plans under ERISA, wage theft and unpaid overtime, consumer fraud, and dangerous and defective drugs and medical devices.
This press release may be considered Attorney Advertising in some jurisdictions. No class has been certified in this case, so counsel does not represent you unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing now. Your ability to share in any potential future recovery does not depend on serving as lead plaintiff.
